ArticleEndocrine-related cancer2019

Low PR in ER(+)/HER2(-) breast cancer: high rates of TP53 mutation and high SUV.

Sung Gwe Ahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.